Aster DM Health.

Market Cap: Small Cap
Industry: Hospital
ISIN: INE914M01019
NSEID: ASTERDM
BSEID: 540975

INR

634.85

-17.9 (-2.74%)

BSENSE

Dec 05

BSE+NSE Vol: 3.73 lacs

{
  "main_header": {
    "sid": 1002923,
    "name": "Aster DM Health.",
    "stock_name": "Aster DM Health.",
    "full_name": "Aster DM Healthcare Ltd",
    "name_url": "stocks-analysis/aster-dm-health",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "634.85",
    "chg": -17.9,
    "chgp": "-2.74%",
    "dir": -1,
    "prev_price": "652.75",
    "mcapval": "32,892.91 Cr",
    "mcap": "Small Cap",
    "scripcode": 540975,
    "symbol": "ASTERDM",
    "ind_name": "Hospital",
    "ind_code": 94,
    "indexname": "",
    "isin": "INE914M01019",
    "curr_date": "Dec 05",
    "curr_time": "",
    "bse_nse_vol": "3.73 lacs",
    "exc_status": "Active",
    "traded_date": "Dec 05, 2025",
    "traded_date_str": "2025 12 05",
    "score": "",
    "scoreText": "",
    "Live": 1,
    "market_time": 1,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/aster-dm-health-1002923-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0,
      "all_data": []
    }
  },
  "news": {
    "results": [
      {
        "title": "Is Aster DM Health. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-aster-dm-health-overvalued-or-undervalued-3742839",
        "imagepath": "",
        "date": "2025-12-03 08:24:55",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Valuation Metrics Indicate Premium Pricing</strong></p>\n<p>Aster DM Healthcare trades at a price-to-earnings (PE) ratio of 92.0, significantly higher than many of its hospital sector peers. Its price-to-book value stands at 7.6, while the enterprise value to EBITDA ratio is 42.1, underscoring the market’s willingness to pay a steep premium for the company’s earnings and asset base. These multiples place Aster firmly in the ‘expensive’ category, reflecting elevated expectations for future growth and profitability.</p>\n<p>Compared to competitors such as Apollo Hospitals, which is rated as ‘attractive’ with a PE ratio closer to 62, and Narayana Hrudaya, also ‘expensive’ but with a PE near 46, Aster’s valuation is on the higher end. Even some ‘very expensive’ peers like Max Healthcare and Fortis..."
      },
      {
        "title": "Aster DM Healthcare Valuation Shifts Highlight Price Attractiveness in Hospital Sector",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/aster-dm-healthcare-valuation-shifts-amidst-strong-returns-and-sector-comparisons-3739869",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/AsterDMHealthca_valuationdot_3739869.png",
        "date": "2025-12-02 08:00:38",
        "description": "Aster DM Healthcare’s recent valuation metrics reveal a notable shift in price attractiveness within the hospital sector, reflecting changes in key financial ratios such as price-to-earnings and price-to-book value. This article examines these valuation parameters in the context of historical trends and peer comparisons, offering insights into the company’s market positioning and investment appeal."
      },
      {
        "title": "Aster DM Health Sees Revision in Market Evaluation Amid Mixed Financial Signals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/aster-dm-health-upgraded-from-sell-to-hold-by-marketsmojo-on-7-nov-2025-3738018",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/AsterDMHealth_mojoScore_3738018.png",
        "date": "2025-12-01 10:09:27",
        "description": "Aster DM Health has experienced a revision in its market evaluation, reflecting a nuanced shift in its financial and technical outlook. This change comes amid a backdrop of steady returns and contrasting fundamental indicators, prompting a reassessment of the company’s position within the hospital sector."
      },
      {
        "title": "Is Aster DM Health. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-aster-dm-health-overvalued-or-undervalued-3716825",
        "imagepath": "",
        "date": "2025-11-20 08:08:34",
        "description": "As of 19 November 2025, the valuation grade for Aster DM Health has moved from very expensive to expensive. The company is currently considered overvalued based on its high PE ratio of 91.71, a Price to Book Value of 7.58, and an EV to EBITDA of 41.94. These ratios significantly exceed those of its peers, such as Apollo Hospitals with a PE of 64.09 and EV to EBITDA of 33.69, indicating a substantial premium for Aster DM Health.\n\nIn comparison to its peers, Aster DM Health's PEG ratio stands at 0.00, which is notably lower than that of Narayana Hrudaya at 4.95, further emphasizing the overvaluation. Despite a strong year-to-date stock return of 29.06% compared to the Sensex's 9.02%, the elevated valuation ratios suggest that the stock may not sustain its current price levels in the long term...."
      },
      {
        "title": "Aster DM Healthcare Technical Momentum Shifts Amid Mixed Market Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/aster-dm-healthcare-technical-momentum-shifts-amid-mixed-market-signals-3717155",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/AsterDMHealthca_technicaldot_3717155.png",
        "date": "2025-11-20 08:08:17",
        "description": "Aster DM Healthcare has experienced a nuanced shift in its technical momentum, reflecting a complex interplay of market indicators. The stock’s recent price movement and technical signals reveal a transition from a bullish trend to a more mildly bullish stance, underscoring evolving investor sentiment within the hospital sector."
      },
      {
        "title": "Aster DM Healthcare Valuation Shift Highlights Price Attractiveness Amid Sector Peers",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/aster-dm-healthcare-valuation-shifts-price-attractiveness-under-scrutiny-amid-elevated-multiples-3717055",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/AsterDMHealthca_valuationdot_3717055.png",
        "date": "2025-11-20 08:00:55",
        "description": "Aster DM Healthcare's recent valuation parameters reveal a notable shift in price attractiveness within the hospital sector, reflecting changes in key metrics such as price-to-earnings (P/E) and price-to-book value (P/BV) ratios. This article analyses these valuation adjustments in the context of historical data and peer comparisons, providing investors with a comprehensive view of the company's market standing."
      },
      {
        "title": "Aster DM Healthcare Adjusts Financial Evaluation Amid Mixed Performance Indicators",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/aster-dm-healthcare-stock-rating-upgraded-to-hold-amid-mixed-financial-performance-3684604",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/AsterDMHealthca_mojoScore_3684604.png",
        "date": "2025-11-10 08:15:41",
        "description": "Aster DM Healthcare has recently adjusted its financial evaluation, reflecting stable quarterly performance with significant metrics. While the company achieved high operating profit and net sales, it faces challenges such as a decline in PAT and low debtor turnover, despite strong market performance and management efficiency."
      },
      {
        "title": "Aster DM Healthcare's Quality Grade Change Reflects Resilience Amid Market Challenges",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/aster-dm-healthcare-upgrades-quality-grade-from-below-average-to-average-3684311",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/AsterDMHealthca_qualitydot_3684311.png",
        "date": "2025-11-10 08:00:34",
        "description": "Aster DM Healthcare has undergone an evaluation revision, reflecting its solid performance in financial metrics despite recent sales growth challenges. The company maintains a strong EBIT to interest ratio and manageable debt levels, showcasing operational stability and competitive positioning within the hospital industry compared to its peers."
      },
      {
        "title": "How has been the historical performance of Aster DM Health.?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-aster-dm-health-3683585",
        "imagepath": "",
        "date": "2025-11-09 22:43:12",
        "description": "Answer:\nThe historical performance of Aster DM Health shows significant fluctuations in key financial metrics over the years.\n\nBreakdown:\nAster DM Health's net sales have increased from 2,994.05 Cr in Mar'23 to 4,138.46 Cr in Mar'25, indicating a strong upward trend. However, total operating income peaked at 10,253.28 Cr in Mar'22 before declining to 4,138.46 Cr in Mar'25. The total expenditure, excluding depreciation, rose from 2,544.97 Cr in Mar'23 to 3,373.93 Cr in Mar'25, reflecting increased operational costs. Operating profit (PBDIT) also showed improvement, rising from 449.08 Cr in Mar'23 to 764.53 Cr in Mar'25, while profit before tax increased from 206.68 Cr in Mar'23 to 489.97 Cr in Mar'25. Profit after tax followed a similar trend, growing from 170.81 Cr in Mar'23 to 355.60 Cr in Mar'25. The earnings per share (EPS) surged dramatically from 8.51 in Mar'23 to 107.66 in Mar'25. On the balance sheet..."
      }
    ],
    "total": 230,
    "sid": "1002923",
    "stock_news_url": "https://www.marketsmojo.com/news/aster-dm-healthcare-1002923"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation",
      "datetime": "03-Dec-2025",
      "details": "We wish to inform that the Company through its representatives will be participating in the Bengaluru Corporate Day 2025 organized by Elara Capital Bengaluru scheduled on December 08 2025. Request you to kindly take the above information on record.",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation",
      "datetime": "23-Nov-2025",
      "details": "Intimation regarding the participation of representatives of the Company in the investor conference scheduled on 27th Nov 2025",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation",
      "datetime": "23-Nov-2025",
      "details": "Intimation regarding the participation of representatives of the Company in the investor conferences scheduled on 26th Nov 2025",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Aster DM Healthcare Ltd has declared <strong>10%</strong> dividend, ex-date: 28 Aug 25",
          "dt": "2025-08-28",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Is Aster DM Health. overvalued or undervalued?

2025-12-03 08:24:55

Valuation Metrics Indicate Premium Pricing

Aster DM Healthcare trades at a price-to-earnings (PE) ratio of 92.0, significantly higher than many of its hospital sector peers. Its price-to-book value stands at 7.6, while the enterprise value to EBITDA ratio is 42.1, underscoring the market’s willingness to pay a steep premium for the company’s earnings and asset base. These multiples place Aster firmly in the ‘expensive’ category, reflecting elevated expectations for future growth and profitability.

Compared to competitors such as Apollo Hospitals, which is rated as ‘attractive’ with a PE ratio closer to 62, and Narayana Hrudaya, also ‘expensive’ but with a PE near 46, Aster’s valuation is on the higher end. Even some ‘very expensive’ peers like Max Healthcare and Fortis...

Aster DM Healthcare Valuation Shifts Highlight Price Attractiveness in Hospital Sector

2025-12-02 08:00:38

Aster DM Healthcare’s recent valuation metrics reveal a notable shift in price attractiveness within the hospital sector, reflecting changes in key financial ratios such as price-to-earnings and price-to-book value. This article examines these valuation parameters in the context of historical trends and peer comparisons, offering insights into the company’s market positioning and investment appeal.

Aster DM Health Sees Revision in Market Evaluation Amid Mixed Financial Signals

2025-12-01 10:09:27

Aster DM Health has experienced a revision in its market evaluation, reflecting a nuanced shift in its financial and technical outlook. This change comes amid a backdrop of steady returns and contrasting fundamental indicators, prompting a reassessment of the company’s position within the hospital sector.

Is Aster DM Health. overvalued or undervalued?

2025-11-20 08:08:34

As of 19 November 2025, the valuation grade for Aster DM Health has moved from very expensive to expensive. The company is currently considered overvalued based on its high PE ratio of 91.71, a Price to Book Value of 7.58, and an EV to EBITDA of 41.94. These ratios significantly exceed those of its peers, such as Apollo Hospitals with a PE of 64.09 and EV to EBITDA of 33.69, indicating a substantial premium for Aster DM Health. In comparison to its peers, Aster DM Health's PEG ratio stands at 0.00, which is notably lower than that of Narayana Hrudaya at 4.95, further emphasizing the overvaluation. Despite a strong year-to-date stock return of 29.06% compared to the Sensex's 9.02%, the elevated valuation ratios suggest that the stock may not sustain its current price levels in the long term....

Aster DM Healthcare Technical Momentum Shifts Amid Mixed Market Signals

2025-11-20 08:08:17

Aster DM Healthcare has experienced a nuanced shift in its technical momentum, reflecting a complex interplay of market indicators. The stock’s recent price movement and technical signals reveal a transition from a bullish trend to a more mildly bullish stance, underscoring evolving investor sentiment within the hospital sector.

Aster DM Healthcare Valuation Shift Highlights Price Attractiveness Amid Sector Peers

2025-11-20 08:00:55

Aster DM Healthcare's recent valuation parameters reveal a notable shift in price attractiveness within the hospital sector, reflecting changes in key metrics such as price-to-earnings (P/E) and price-to-book value (P/BV) ratios. This article analyses these valuation adjustments in the context of historical data and peer comparisons, providing investors with a comprehensive view of the company's market standing.

Aster DM Healthcare Adjusts Financial Evaluation Amid Mixed Performance Indicators

2025-11-10 08:15:41

Aster DM Healthcare has recently adjusted its financial evaluation, reflecting stable quarterly performance with significant metrics. While the company achieved high operating profit and net sales, it faces challenges such as a decline in PAT and low debtor turnover, despite strong market performance and management efficiency.

Aster DM Healthcare's Quality Grade Change Reflects Resilience Amid Market Challenges

2025-11-10 08:00:34

Aster DM Healthcare has undergone an evaluation revision, reflecting its solid performance in financial metrics despite recent sales growth challenges. The company maintains a strong EBIT to interest ratio and manageable debt levels, showcasing operational stability and competitive positioning within the hospital industry compared to its peers.

How has been the historical performance of Aster DM Health.?

2025-11-09 22:43:12

Answer: The historical performance of Aster DM Health shows significant fluctuations in key financial metrics over the years. Breakdown: Aster DM Health's net sales have increased from 2,994.05 Cr in Mar'23 to 4,138.46 Cr in Mar'25, indicating a strong upward trend. However, total operating income peaked at 10,253.28 Cr in Mar'22 before declining to 4,138.46 Cr in Mar'25. The total expenditure, excluding depreciation, rose from 2,544.97 Cr in Mar'23 to 3,373.93 Cr in Mar'25, reflecting increased operational costs. Operating profit (PBDIT) also showed improvement, rising from 449.08 Cr in Mar'23 to 764.53 Cr in Mar'25, while profit before tax increased from 206.68 Cr in Mar'23 to 489.97 Cr in Mar'25. Profit after tax followed a similar trend, growing from 170.81 Cr in Mar'23 to 355.60 Cr in Mar'25. The earnings per share (EPS) surged dramatically from 8.51 in Mar'23 to 107.66 in Mar'25. On the balance sheet...

View All News

Announcement

Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

03-Dec-2025 | Source : BSE

We wish to inform that the Company through its representatives will be participating in the Bengaluru Corporate Day 2025 organized by Elara Capital Bengaluru scheduled on December 08 2025. Request you to kindly take the above information on record.